Noggin Over-expression Modulates the Malignant Behavior of AML - Khoury, Haytham
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
16 °P sammeln
  • Broschiertes Buch

Acute Myeloid Leukemia is a deadly disease. Although our knowledge regarding the mechanisms that govern the leukemic transformation has largely increased over the last 20 years, much is still to be discovered. Deciphering these mechanisms is crucial for better understanding the pathogenesis of this fatal illness and also for the development of new strategies for treating it. In the present work, the author unveils a new mechanism that contributes to the pathogenesis of this disease. This mechanism is namely the overexpression of the secreted protein Noggin. Noggin is an inhibitor of the bone…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Acute Myeloid Leukemia is a deadly disease. Although our knowledge regarding the mechanisms that govern the leukemic transformation has largely increased over the last 20 years, much is still to be discovered. Deciphering these mechanisms is crucial for better understanding the pathogenesis of this fatal illness and also for the development of new strategies for treating it. In the present work, the author unveils a new mechanism that contributes to the pathogenesis of this disease. This mechanism is namely the overexpression of the secreted protein Noggin. Noggin is an inhibitor of the bone morphogentic proteins. Noggin overexpression is shown, in this research, to be a very frequent molecular event in acute myeloid leukemia leukemia, leading to abrogation of both the canonical and the non-canonical bone morphogentic protein pathways. Furthermore, Noggin increases the proliferation and the self-renewal of leukemic progenitors and also protects the leukemic cells against the cytotoxic effect of the chemotherapy daunorubicin. Indeed, these findings suggest that Noggin suppression could be an interesting target for the treatment of acute myeloid leukemia.
Autorenporträt
The author is a physician. He obtained his diploma of medicine from the Aleppo University (Syria) and his specialty in Hematology from the University of Rennes (France). Then, He completed a fellowship in bone marrow transplantation at Vancouver General Hospital(Canada)and a Master of Science at the University of Toronto (Canada).